Opendata, web and dolomites

GNA NOW SIGNED

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "GNA NOW" data sheet

The following table provides information about the project.

Coordinator
STICHTING LYGATURE 

Organization address
address: JAARBEURSPLEIN 6
city: UTRECHT
postcode: 3521 AL
website: http://www.lygature.org/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 31˙415˙987 €
 EC max contribution 12˙299˙995 € (39%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2018-16-single-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2025-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING LYGATURE NL (UTRECHT) coordinator 620˙681.00
2    NOSOPHARM FR (LYON CEDEX 03) participant 4˙069˙500.00
3    NORTH BRISTOL NATIONAL HEALTH SERVICE TRUST UK (BRISTOL) participant 2˙422˙556.00
4    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 1˙495˙300.00
5    HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH DE (BRAUNSCHWEIG) participant 1˙268˙750.00
6    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 1˙198˙125.00
7    THE UNIVERSITY OF LIVERPOOL UK (LIVERPOOL) participant 430˙523.00
8    BIOASTER FONDATION DE COOPERATION SCIENTIFIQUE FR (LYON) participant 308˙896.00
9    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) participant 300˙000.00
10    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 185˙662.00
11    EVOTEC INTERNATIONAL GMBH DE (HAMBURG) participant 0.00

Map

 Project objective

AntiMicrobial Resistance (AMR) is a global and serious threat to human health. Gram-negative bacteria are widely regarded as the culprit representing one of the gravest dangers. Indeed, there is a dearth of new agents able to address AMR in Gram-negative bacteria, especially compounds with novel modes of action. Finding and developing such compounds represents a huge scientific challenge, one that requires the collaboration of stakeholders bringing many different kinds of expertise. The world is coming together to tackle this issue and public-private partnerships represent an attractive way to hasten the pace and increase the probability of successfully identifying and developing novel antibiotics.

Under the global umbrella of the AMR Accelerator, the Gram-Negative Antibacterials-NOW (GNA NOW) consortium pledges to a 6-years commitment to bring together key European academic and private experts in antibiotic discovery and development in order to support and manage a portfolio of novel mode of action drugs against Gram-negative bacteria. Starting with three initial compounds/series, dedicated project teams will work together to define and execute the most efficient project plans. The consortium will put in place robust governance and management structures to ensure that the most promising compounds are pursued diligently. Ultimately, the goal of GNA NOW is to progress one compound through completion of phase I studies plus one compound reaching Investigational New Drug (IND) stage and/or up to two compounds reaching clinical development candidate stage.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GNA NOW" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GNA NOW" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More  

STOPFOP (2019)

Saracatinib Trial tO Prevent FOP

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More